Comparison Between Amiodarone And Lidocaine With Magnesium Sulfate On Reperfusion Ventriculare Fibrillation After Aortic Cross Clamp Release

Comparison Between The Effect Of Amiodarone And Lidocaine With Magnesium Sulfate On Occurrenc Of Reperfusion Ventriculare Fibrillation After Aortic Cross Clamp Release On Aortic Valve Surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201801002824375

Enrollment

Registered

2017-11-29

Start date

2016-01-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System reperfusion ventricular fibrillation before aortic cross clamp release Cardiology

Interventions

amiodarone

lidocaine 2% and magnesium sulfate

normal saline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ¿ Patient with aortic valve disease

Exclusion criteria

Exclusion criteria: ¿History of treatment with digoxin, amiodarone, or lidocaine (including cardiopulmonary resuscitation) ¿Contraindications to amiodarone (sick sinus syndrome, atrioventricular conduction abnormalities, thyroid disease, interstitial lung disorders, renal or liver disease, and known allergic or toxic reactions to amiodarone) ¿Combined cardiac surgery, and emergent operation.

Design outcomes

Primary

Measure	Time frame
incidence of VF requiring defibrillation during 30 minutes after aortic cross clamp release	—

Secondary

Measure	Time frame
number of defibrillation needed	—

Countries

Egypt

Contacts

Public ContactHazem Abd El-wahab

Lecturer of Anesthesiology Faculty of Medicine, Beni - Suief University

hazem.hussien@med.bsu.edu.eg+201153517862

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026